Human prion diseases: Epidemiology and integrated risk assessment

Lancet Neurology

Volumn 2, Issue 12, 2003, Pages 757-763

  Glatzel, Markus ^a   Ott, Peter M ^b   Linder, Thomas ^c   Gebbers, Jan O ^d   Gmür, Arnold ^e   Wüst, Werner ^e   Huber, Gerhard ^f   Moch, Holger ^g   Podvinec, Michael ^h   Stamm, Bernhard ^h   Aguzzi, Adriano ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c LUZERNER KANTONSSPITAL   (Switzerland)

^d Pathologische Institut am Kantonsspital Luzern   (Switzerland)

^e KANTONSSPITAL   (Switzerland)

^f UNIVERSITY HOSPITAL BASEL   (Switzerland)

^g UNIVERSITY HOSPITAL BASEL   (Switzerland)

^h CANTONAL HOSPITAL AARAU   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTECHNOLOGY; CLINICAL EXAMINATION; CREUTZFELDT JAKOB DISEASE; DIAGNOSTIC PROCEDURE; DISEASE TRANSMISSION; EPIDEMIOLOGICAL DATA; GENETIC ANALYSIS; HUMAN; INCIDENCE; NONHUMAN; POPULATION RESEARCH; PREVALENCE; PRION DISEASE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; STATISTICAL ANALYSIS; SWITZERLAND; ZOONOSIS;

EID: 0344420049     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(03)00588-X     Document Type: Note

References (44)

1. Prusiner S.B. Prions. Proc Natl Acad Sci USA. 95:1998;13363-13383.
2. Aguzzi A., Montrasio F., Kaeser P.S. Prions: health scare and biological challenge. Nat Rev Mol Cell Biol. 2:2001;118-126.
3. Prusiner S.B. Novel proteinaceous infectious particles cause scrapie. Science. 216:1982;136-144.
4. Aguzzi A., Heikenwalder M. Prion diseases: Cannibals and garbage piles. Nature. 423:2003;127-129.
5. Aguzzi A., Weissmann C. Prion research: the next frontiers. Nature. 389:1997;795-798.
6. Brandel J.P., Delasnerie-Laupretre N., Laplanche J.L., Hauw J.J., Alperovitch A. Diagnosis of Creutzfeldt-Jakob disease: effect of clinical criteria on incidence estimates. Neurology. 54:2000;1095-1099.
7. Aguzzi A., Weissmann C. Sleepless in Bologna: transmission of fatal familial insomnia. Trends Microbiol. 4:1996;129-131.
8. Hill A.F., Desbruslais M., Joiner S., et al. The same prion strain causes vCJD and BSE. Nature. 389:1997;448-450.
9. Bruce M.E., Will R.G., Ironside J.W., et al. Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent. Nature. 389:1997;498-501.
10. Aguzzi A., Weissmann C. Spongiform encephalopathies: a suspicious signature. Nature. 383:1996;666-667.
11. The Department of Health. Monthly CJD, Statistics. http://www.doh.gov.uk/ cjd/cjd_stat.htm (accessed Nov 1, 2003).
12. Valleron A.J., Boelle P.Y., Will R., Cesbron J.Y. Estimation of epidemic size and incubation time based on age characteristics of vCJD in the United Kingdom. Science. 294:2001;1726-1728.
13. Aguzzi A, Hegyi I, Peltola M, Glatzel M. Rapport des activitées 1996-1999. Hôpital universitaire de Zurich. Département de pathologie. Institut de neuropathologie. Centre nationale de référence pour les prionoses (NRPE). 2000.
14. Glatzel M., Rogivue C., Ghani A., Streffer J.R., Amsler L., Aguzzi A. Incidence of Creutzfeldt-Jakob disease in Switzerland. Lancet. 360:2002;139-141.
15. Zerr I., Pocchiari M., Collins S., et al. Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt-Jakob disease. Neurology. 55:2000;811-815.
16. Saiz A., Nos C., Yague J., Dominguez A., Graus F., Munoz P. The impact of the introduction of the 14-3-3 protein assay in the surveillance of sporadic Creutzfeldt-Jakob disease in Catalonia. J Neurol. 248:2001;592-594.
17. Cohen C.H. Does improvement in case ascertainment explain the increase in sporadic Creutzfeldt-Jakob disease since 1970 in the United Kingdom? Am J Epidemiol. 152:2000;474-479.
18. Goldfarb L.G., Brown P., Mitrova E., et al. Creutzfeldt-Jacob disease associated with the PRNP codon 200Lys mutation: an analysis of 45 families. Eur J Epidemiol. 7:1991;477-486.
19. Jackson G.S., Beck J.A., Navarrete C., et al. HLA-DQ7 antigen and resistance to variant CJD. Nature. 414:2001;269-270.
20. Pepys M.B., Bybee A., Booth D.R., et al. MHC typing in variant Creutzfeldt-Jakob disease. Lancet. 361:2003;487-489.
21. Foster J.D., Bruce M., McConnell I., Chree A., Fraser H. Detection of BSE infectivity in brain and spleen of experimentally infected sheep. Vet Rec. 138:1996;546-548.
22. Bons N., Mestre-Frances N., Belli P., Cathala F., Gajdusek D.C., Brown P. Natural and experimental oral infection of nonhuman primates by bovine spongiform encephalopathy agents. Proc Natl Acad Sci USA. 96:1999;4046-4051.
23. Glatzel M., Abela E., Maissen M., Aguzzi A. Extraneural pathological prion protein in sporadic Creutzfeldt-Jakob disease. N Engl J Med. 349:2003;1812-1820.
24. Collins S., Law M.G., Fletcher A., Boyd A., Kaldor J., Masters C.L. Surgical treatment and risk of sporadic Creutzfeldt-Jakob disease: a case-control study. Lancet. 353:1999;693-697.
25. Office international des epizooties. Bovine spongiform encephalopathy (BSE). http://www.oie.int/eng/info/en_esb.htm (accessed Nov 1, 2003).
26. Department of the Environment Food Rural Affairs. DEFRA BSE information: monthly graphs. http://www.defra.gov.uk/animalh/bse/bse-statistics/level-4- graphs.html (accessed Nov 1, 2003).
27. Bundesamt fur Veterinärwesen. BSE: in kurtz. http://www.bvet.admin. ch/focus_bse/d/0_subfr-intern_kurz.html (accessed Nov 1, 2003).
28. Zerr I., Poser S. Clinical diagnosis and differential diagnosis of CJD and vCJD: with special emphasis on laboratory tests. Apmis. 110:2002;88-98.
29. Asante E.A., Linehan J.M., Desbruslais M., et al. BSE prions propagate as either variant CJD-like or sporadic CJD-like prion strains in transgenic mice expressing human prion protein. Embo J. 21:2002;6358-6366.
30. Beekes M., Baldauf E., Diringer H. Sequential appearance and accumulation of pathognomonic markers in the central nervous system of hamsters orally infected with scrapie. J Gen Virol. 77:1996;1925-1934.
31. Glatzel M., Aguzzi A. PrP(C) expression in the peripheral nervous system is a determinant of prion neuroinvasion. J Gen Virol. 81:2000;2813-2821.
32. EC commission. Official report on the situation concerning BSE in Switzerland. http://europa.eu.int/comm/food/fs/sc/ssc/out136_en.pdf (accessed Nov 1, 2003).
33. Hope J., Wood S.C., Birkett C.R., et al. Molecular analysis of ovine prion protein identifies similarities between BSE and an experimental isolate of natural scrapie, CH1641. J Gen Virol. 80:1999;1-4.
34. Bruce M.E., Boyle A., Cousens S., et al. Strain characterization of natural sheep scrapie and comparison with BSE. J Gen Virol. 83:2002;695-704.
35. Hill A.F., Butterworth R.J., Joiner S., et al. Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples. Lancet. 353:1999;183-189.
36. Hilton D.A., Ghani A.C., Conyers L., et al. Accumulation of prion protein in tonsil and appendix: review of tissue samples. BMJ. 325:2002;633-634.
37. Aguzzi A. Prion diseases, blood and the immune system: concerns and reality. Haematologica. 85:2000;3-10.
38. Glatzel M., Aguzzi A. Peripheral pathogenesis of prion diseases. Microbes Infect. 2:2000;613-619.
39. Aguzzi A., Glatzel M., Montrasio F., Prinz M., Heppner F.L. Interventional strategies against prion diseases. Nat Rev Neurosci. 2:2001;745-749.
40. Meier P., Genoud N., Prinz M., et al. Soluble dimeric prion protein binds PrP(Sc) in vivo and antagonizes prion disease. Cell. 113:2003;49-60.
41. Montrasio F., Frigg R., Glatzel M., et al. Impaired prion replication in spleens of mice lacking functional follicular dendritic cells. Science. 288:2000;1257-1259.
42. Heppner F.L., Musahl C., Arrighi I., et al. Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies. Science. 294:2001;178-182.
43. White A.R., Enever P., Tayebi M., et al. Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature. 422:2003;80-83.
44. Heppner F.L., Arrighi I., Kalinke U., Aguzzi A. Immunity against prions? Trends mol med. 7:2001;477-479.